TB-500 vs Thymosin β4
A synthetic thymosin β4 fragment marketed for recovery; preclinical evidence. An endogenous actin-sequestering peptide involved in wound healing. Side by side: type, evidence tier, receptor, molecular weight, and half-life — the same fields as each monograph, rearranged so the engineering difference is visible.
TB-500 | Thymosin β4 Tβ4 | |
|---|---|---|
| Also known as | — | — |
| Type | Research | Endogenous |
| Evidence | Preclinical | Established |
| Family | Repair & regenerative | Repair & regenerative |
| Class | Synthetic thymosin β4 fragment / analog | Actin-binding peptide (43 aa) |
| Receptor | Same actin-related biology as thymosin β4 (not receptor-mediated) | No classical receptor; sequesters monomeric (G-)actin |
| Molecular weight | — | ~4,963.4 Da |
| Half-life | Poorly characterized in humans | Poorly characterized in humans |
| Based on | Thymosin β4 | Native hormone |
Half-life bars are on a logarithmic scale across the molecules shown. Reference values for the native or representative form — educational only, not medical or dosing advice.
Common questions
- What is the difference between TB-500 and Thymosin β4?
- TB-500 is a research peptide based on Thymosin β4; Thymosin β4 is an endogenous hormone. TB-500 signals at Same actin-related biology as thymosin β4 (not receptor-mediated); Thymosin β4 signals at No classical receptor; sequesters monomeric (G-)actin.
- How do the half-lives of TB-500 and Tβ4 compare?
- The reported circulating half-life of TB-500 is Poorly characterized in humans; Thymosin β4 is Poorly characterized in humans. These are reference values for the native or representative form — educational only, not dosing advice.
Prefer the other order? Thymosin β4 vs TB-500. Or open the interactive comparison tool to add more molecules.